CJC-1131. ConjuChem.

Abstract

ConjuChem is developing CJC-1131, a drug affinity complex conjugate of glucagon-like peptide 1 for the potential treatment of type 2 diabetes. In August 2003, a phase I/II trial was completed and a phase II trial was expected to begin in October.

• Authors: Nick Giannoukakis
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 4 Issue 10 Pg. 1245-9 (Oct 2003) ISSN: 1472-4472 [Print] England
• PMID: 14649218 (Publication Type: Journal Article, Review)

Chemical References

• CJC 1131
• Hypoglycemic Agents
• Maleimides
• Peptides

Topics

• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Humans
• Hypoglycemic Agents (adverse effects, chemical synthesis, pharmacokinetics, pharmacology, therapeutic use)
• Maleimides (adverse effects, chemical synthesis, pharmacokinetics, pharmacology, therapeutic use)
• Peptides (adverse effects, chemical synthesis, pharmacokinetics, pharmacology, therapeutic use)
• Structure-Activity Relationship